Moberg Pharma Ab · OMXSTO:MOB
Moberg Pharma Ab — Redeye Healthcare Day 2026
17 slides from Moberg Pharma Ab's conference presentation, Apr 14, 2026
Slide 1: A novel topical treatment for onychomycosis
A novel topical treatment for onychomycosis – introducing Terclara® April 14, 2026 Redeye Healthcare Day, Stockholm Anna Ljung, CEO
Slide 2: Disclaimer
Disclaimer The purpose of this presentation (the "Presentation") is to provide an overview of Moberg Pharma AB (publ) (the "Company"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any wr
Slide 3: Potential new global market leader in Onychomycosis
Potential new global market leader in Onychomycosis Terclara® is a new Market approvals Very successful launch in topical treatment for nail in place in 13 European Scandinavia, European fungus based on countries rollout ongoing terbinafine
Slide 4: Oral terbinafine is the gold standard for treatment of toenail fungus
Oral terbinafine is the gold standard for treatment of toenail fungus x40 Terclara® delivers terbinafine terbinafine in nailbed directly and effectively to the nail with Terclara® vs levels seen with oral treatment* x1,000 76% less terbinafine with Terclara® (MOB-015) in mycological cure* plasma vs
Slide 5: Why does Terclara win with patients?
Why does Terclara® win with patients? ▸ Kills the fungus ▸ It is safe ▸ Easy to apply ▸ Quick visible improvement * Mantap marketing survey, 2023
Slide 6: Strong premium position from true advantage
Strong premium position from true advantage Terclara´s mycological cure rate OTC Terabinafin allows for a price premium Mycological cure 76% Mycological cure OTC Amorolfin Mycological cure approx. 20%* Products based on devices Unclear to low cure Cosmetic Medical
Slide 7: 70+ million patients in Europe need better treatment for nail fungus
70+ million patients in Europe need better treatment for nail fungus 10% of the population 7/10 doctors avoid prescribing suffer from nail terbinafine tablets2 fungus1 USD 2bn global onychomycosis market.3 1) PLoS Pathog. 2014 Jun; 10(6): e1004105. 2) due to patients´ concerns for serious side effec
Slide 8: Strong drivers behind underlying market growth
Strong drivers behind underlying market growth 1. High prevalence 2. Aging population 3. Lifestyle factors 4. Growing aesthetic concerns 5. Rising awareness and willingness to treat * Grand View Research, Mordorin Intelligence, GMI, Research & Markets
Slide 9: Terclara expands the market
Terclara® expands the market Terclara’s strong proposition for consumers 100% prevalence unlocks the market growth = 100% usage potential Conversion of non- treaters 44% do not Growth potential treat Conversion Market of “mal- potential treaters” Users of Increased deferior frequency products Satisf
Slide 10: Terclara maintains its market leading position in Sweden as second launch year progresses
Terclara® maintains its market leading position in Sweden as second launch year progresses Terclara® has become the clear market leader and driven category growth – in a highly competitive 42% 35% market 11% Terclara® Terclara® value share volume share no. of units Increase in Terclara® market share
Slide 11: Awarded 'Launch of the year' 2024 by major Swedish pharmacies
Awarded ’Launch of the year’ 2024 by major Swedish pharmacies DOZ pharmacy chain: 'A world class launch that has revitalized the category. The product has quickly become a market leader, driving progress forward and helping us gain market share. With the support of educational materials, we have tog
Slide 12: Terclara market leader also in Norway
Terclara® market leader also in Norway despite consumer marketing only commencing in April Terclara® launch nominated for “Launch of the Year 2025” by the pharmacy chains Apotek 1 and Alliance 34% 31% Healthcare Builds on the same proven Terclara® Terclara® model as the Swedish launch: value share v
Slide 13: Strong commercial partners in place
Strong commercial partners in place • Partners in place for Europe, Canada, Scandinavia, Israel • Latest addition: Karo Healthcare, a capable partner with global reach – Lamisil®: The leading global brand for onychomycosis – Established distribution across all major pharmacies – Proven ability to ma
Slide 14: Terclara is approved in 13 European countries
Terclara® is approved in 13 European countries Market approvals • Austria - OTC • France - Rx • Norway - • Belgium - OTC • Hungary - OTC OTC • Czech Rep. - Rx • Ireland - Rx • Spain - Rx • Denmark - Rx • Italy - OTC • Sweden - OTC • Finland - Rx • Netherlands - OTC Pipeline of additional approvals f
Slide 15: Moberg Pharma, a pharma company with a strong track record
Behind Terclara: Moberg Pharma, a pharma company with a strong track record • Moberg Pharma’s R&D is based on discoveries of late Dr. Sven Moberg of Sahlgrenska University Hospital in Gothenburg, Sweden. • All Moberg Pharma products contains a patented keratolytic carrier which also promotes the vis
Slide 16: Executive summary
Executive summary ► Unprecedented ability to ► Terclara® became the market kill dermatophytes: 76% of patients leader in Sweden and Norway became fungus free, in two phase 3- instantly after starting consumer studies (800+ patients) marketing ► Terbinafine, the gold standard active for ► Partners in
Slide 17: Anna Ljung, CEO
Anna Ljung, CEO +46 707 66 60 30, anna.ljung@mobergpharma.se